Merck KGaA - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 119 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Merck KGaA - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Merck KGaA - Product Pipeline Review - 2014', provides an overview of the Merck KGaA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Merck KGaA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Merck KGaA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Merck KGaA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Merck KGaA's pipeline products

Reasons to buy

- Evaluate Merck KGaA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Merck KGaA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Merck KGaA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Merck KGaA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Merck KGaA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Merck KGaA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Merck KGaA Snapshot 8
Merck KGaA Overview 8
Key Information 8
Key Facts 8
Merck KGaA - Research and Development Overview 9
Key Therapeutic Areas 9
Merck KGaA - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Pipeline Products - Combination Treatment Modalities 16
Pipeline Products - Partnered Products 17
Partnered Products/Combination Treatment Modalities 18
Pipeline Products - Out-Licensed Products 20
Out-Licensed Products/Combination Treatment Modalities 21
Merck KGaA - Pipeline Products Glance 22
Merck KGaA - Late Stage Pipeline Products 22
Pre-Registration Products/Combination Treatment Modalities 22
Filing rejected/Withdrawn Products/Combination Treatment Modalities 23
Phase III Products/Combination Treatment Modalities 24
Merck KGaA - Clinical Stage Pipeline Products 25
Phase II Products/Combination Treatment Modalities 25
Phase I Products/Combination Treatment Modalities 26
Merck KGaA - Early Stage Pipeline Products 27
IND/CTA Filed Products/Combination Treatment Modalities 27
Preclinical Products/Combination Treatment Modalities 28
Discovery Products/Combination Treatment Modalities 29
Merck KGaA - Drug Profiles 30
cetuximab 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
metformin hydrochloride 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
choriogonadotropin alfa 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ONO-4641 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
sapropterin dihydrochloride 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
tecemotide 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
atacicept 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
DI-17-E-6 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
futuximab 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
MSB-0010445 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
pimasertib hydrochloride 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
pimasertib hydrochloride + SAR-245409 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
plovamer acetate 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
sprifermin 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
MSC-2156119J 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ALX-0761 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
BGB-283 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
DI-B4 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
EMD-1214063 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
EMD-521873 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
MSB-0010360 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
MSB-0010718C 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
MSC-2015103B 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
MSC-2363318A 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Antigen Specific Cancer Immunotherapy-1 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Antigen Specific Cancer Immunotherapy-2 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
AS-605240 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
BeiGene-290 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecule to Inhibit Aurora B Kinase for Pancreatic Cancer 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecule for Oncology 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecule to Inhibit P2X Purinoceptor for Neurodegenerative diseases 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Small Molecule to Inhibit WNT Pathway for Oncology 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecules to Activate TNFR for Cancer 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Merck KGaA - Pipeline Analysis 80
Merck KGaA - Pipeline Products by Target 80
Merck KGaA - Pipeline Products by Route of Administration 83
Merck KGaA - Pipeline Products by Molecule Type 84
Merck KGaA - Pipeline Products by Mechanism of Action 85
Merck KGaA - Recent Pipeline Updates 88
Merck KGaA - Dormant Projects 97
Merck KGaA - Discontinued Pipeline Products 100
Discontinued Pipeline Product Profiles 100
ALX-0761 100
anastrozole 100
atacicept 100
cilengitide 101
cladribine 101
EMD-1204831 101
EMD-387008 101
emfilermin 101
EML-4156 101
EMR-62203 101
FC-EPO 101
matuzumab 102
onercept 102
Osteopontin 102
Oxytocin Receptor Antagonist 102
sarizotan hydrochloride 102
tucotuzumab celmoleukin 102
Merck KGaA - Company Statement 103
Merck KGaA - Locations And Subsidiaries 105
Head Office 105
Other Locations & Subsidiaries 105
Appendix 118
Methodology 118
Coverage 118
Secondary Research 118
Primary Research 118
Expert Panel Validation 118
Contact Us 119
Disclaimer 119

List of Tables
Merck KGaA, Key Information 8
Merck KGaA, Key Facts 8
Merck KGaA - Pipeline by Indication, 2014 11
Merck KGaA - Pipeline by Stage of Development, 2014 14
Merck KGaA - Monotherapy Products in Pipeline, 2014 15
Merck KGaA - Combination Treatment Modalities in Pipeline, 2014 16
Merck KGaA - Partnered Products in Pipeline, 2014 17
Merck KGaA - Partnered Products/ Combination Treatment Modalities, 2014 18
Merck KGaA - Out-Licensed Products in Pipeline, 2014 20
Merck KGaA - Out-Licensed Products/ Combination Treatment Modalities, 2014 21
Merck KGaA - Pre-Registration, 2014 22
Merck KGaA - Filing rejected/Withdrawn, 2014 23
Merck KGaA - Phase III, 2014 24
Merck KGaA - Phase II, 2014 25
Merck KGaA - Phase I, 2014 26
Merck KGaA - IND/CTA Filed, 2014 27
Merck KGaA - Preclinical, 2014 28
Merck KGaA - Discovery, 2014 29
Merck KGaA - Pipeline by Target, 2014 81
Merck KGaA - Pipeline by Route of Administration, 2014 83
Merck KGaA - Pipeline by Molecule Type, 2014 84
Merck KGaA - Pipeline Products by Mechanism of Action, 2014 85
Merck KGaA - Recent Pipeline Updates, 2014 88
Merck KGaA - Dormant Developmental Projects,2014 97
Merck KGaA - Discontinued Pipeline Products, 2014 100
Merck KGaA, Subsidiaries 105